In CML, KMT2D (but also KMT2C) downregulation was found to correlate with the CML phases, and thus, disease progression, but also with the response of CML patients (Rabello et al., 2018). Here, KMT2D is linked to chronic myelogenous leukemia, BCR-ABL1 positive.